Sanofi may win U.S. approval of $3 billion eczema drug by March
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
(Reuters) - French drugmaker Sanofi
Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition.
The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29.
Dupilumab, an injectable antibody drug, is seen by investors as perhaps Sanofi's most promising pipeline medicine, since it has produced promising clinical results and could be first systemic therapy for severe AD.
Industry analysts, on average, forecast annual sales for dupilumab of $3.0 billion by 2021, according to Thomson Reuters Cortellis.
(Reporting by Ben Hirschler; editing by Jason Neely)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fitch Affirms Allergan at 'BBB-'; Outlook Stable
- Gambia's President-Elect says Jammeh cannot reject polls
- Second suspect in Brazilian soccer team air crash put in jail
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!